Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ovarian Neoplasms

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 133 articles: HTML format

Single Articles

June 2026
1. ZHAO M, Huang F, Yang T, Zhang D, et al
   Prognostic value of CA125, HE4, ROMA, and CPH-I in advanced epithelial ovarian cancer.
   BMC Cancer. 2026 Jun 4. doi: 10.1186/s12885-026-16291.
   PubMed     Abstract available
   
   
   
2. DZASOKHOV AS, Khomyakov VM, Turiev AV, Astashov VL, et al
   Adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) in suboptimally cytoreduced advanced ovarian cancer: a randomized phase II trial (PIPAC-OVA).
   BMC Cancer. 2026 Jun 4. doi: 10.1186/s12885-026-16285.
   PubMed     Abstract available
   
   
   May 2026
3. RODMAN EPB, Bhagwate A, Smith HM, Emch MJ, et al
   STAT1 and STAT3 signaling in ovarian cancer: prognostic biomarkers and therapeutic targets.
   BMC Cancer. 2026 May 25. doi: 10.1186/s12885-026-16226.
   PubMed     Abstract available
   
   
   
4. YAMAOKA K, Kume M, Matsumoto A, Hirabatake M, et al
   Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: a retrospective study.
   BMC Cancer. 2026 May 8. doi: 10.1186/s12885-026-16148.
   PubMed     Abstract available
   
   
   
5. WANG J, Wu D, Guo X
   Physical activity, sedentary behavior and ovarian cancer risk in Asian populations: a scoping review and meta-analysis.
   BMC Cancer. 2026 May 5. doi: 10.1186/s12885-026-16079.
   PubMed     Abstract available
   
   
   
6. WEI L, El-Naggar AM, Li Y, Ding Y, et al
   Co-targeting cystathionine gamma-lyase and mTOR: a promising therapeutic strategy in clear cell ovarian cancer.
   BMC Cancer. 2026 May 4. doi: 10.1186/s12885-026-16092.
   PubMed     Abstract available
   
   
   April 2026
7. ZHANG Y, Dai T, Chu D, Zhang W, et al
   Extracellular vesicles derived from ovarian cancer cells promote tumor progression through m2 macrophage polarization and enhanced angiogenesis.
   BMC Cancer. 2026 Apr 24. doi: 10.1186/s12885-026-16059.
   PubMed    
   
   
   
8. WANG Y, Tian M, Zhang H, Zhu H, et al
   Overexpression of COL10A1 in extracellular matrix predicts poor outcome and promotes ovarian cancer progression.
   BMC Cancer. 2026 Apr 10. doi: 10.1186/s12885-026-15959.
   PubMed    
   
   
   
9. ARCH JJ, Uno H, Poort H, Slivjak E, et al
   Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention ('REVITALIZE') to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol.
   BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15936.
   PubMed    
   
   
   
10. LUJEA N, De Leon Rodriguez M, Chiola F, Acosta C, et al
    The physical properties of ascitic fluid enhance metastatic potential by inducing mitotic abnormalities and multinucleation in ovarian cancer.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15683.
    PubMed     Abstract available
    
    
    March 2026
11. FENG Y, Hu Y, Li T, Li M, et al
    XGBoost-Cox modeling with SHAP analysis for survival prediction in ovarian cancer patients: a retrospective cohort study.
    BMC Cancer. 2026 Mar 27. doi: 10.1186/s12885-026-15921.
    PubMed    
    
    
    
12. CSIKOS C, Varga A, Molnar S, Hascsi Z, et al
    The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer.
    BMC Cancer. 2026 Mar 26. doi: 10.1186/s12885-026-15898.
    PubMed    
    
    
    February 2026
13. ANSARI F, Farajkhoda T, Nokhostin F, Zareei Mahmoodabadi H, et al
    Tele-emotion regulation therapy versus tele-guided imagery therapy on sexual performance anxiety in endometrial and ovarian cancer: a randomized clinical trial.
    BMC Cancer. 2026 Feb 21. doi: 10.1186/s12885-025-15180.
    PubMed     Abstract available
    
    
    
14. FU M, Wang J, Wu H, Peng P, et al
    Comprehensive analysis of tissue-derived small extracellular vesicles transcriptomic and extensively targeted lipidomics from patients with high-grade serous ovarian cancer.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15698.
    PubMed    
    
    
    
15. FAROOQ A, Akyuz EM, Cheah BW, Deen S, et al
    Increased cytoplasmic and nuclear S100A6 expression is associated with improved prognosis in ovarian cancer.
    BMC Cancer. 2026 Feb 11. doi: 10.1186/s12885-026-15631.
    PubMed    
    
    
    
16. SHASH E, Vardar MA, Taskiran C, Boujassoum S, et al
    Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications.
    BMC Cancer. 2026 Feb 4. doi: 10.1186/s12885-025-15537.
    PubMed    
    
    
    January 2026
17. GOEL R, Alvi S, Ali R, Sharma P, et al
    Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization.
    BMC Cancer. 2026 Jan 26. doi: 10.1186/s12885-026-15615.
    PubMed     Abstract available
    
    
    
18. LI B, Lou G, Zhang J, Cao N, et al
    Retraction Note: Repression of LncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis.
    BMC Cancer. 2026;26:105.
    PubMed    
    
    
    December 2025
19. ZHAO L, Nie J, Wang J, Li D, et al
    FOXL2 + cancer-associated fibroblasts enhances epithelial ovarian cancer development via TGFbeta/Smad signaling.
    BMC Cancer. 2025 Dec 23. doi: 10.1186/s12885-025-15364.
    PubMed    
    
    
    
20. LI Y, Chen X, Xu Y, Huang S, et al
    Long noncoding RNA BMPR1B-DT promotes anoikis and reduces proliferation in ovarian cancer.
    BMC Cancer. 2025 Dec 18. doi: 10.1186/s12885-025-14656.
    PubMed     Abstract available
    
    
    
21. CHEN L, Ji H, Xie Z, Lin Y, et al
    miR-101-3p represses the migratory and invasive abilities of ovarian cancer cells.
    BMC Cancer. 2025;25:1864.
    PubMed     Abstract available
    
    
    
22. CHEN Q, Dorji JP, Perera SG, Li P, et al
    In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy.
    BMC Cancer. 2025 Dec 10. doi: 10.1186/s12885-025-15435.
    PubMed     Abstract available
    
    
    November 2025
23. LIU X, Zhang M, Hong L, He G, et al
    Characteristics and potential predictors of prematurely terminated interventional clinical trials for ovarian cancer in the ClinicalTrials.gov database.
    BMC Cancer. 2025 Nov 28. doi: 10.1186/s12885-025-15361.
    PubMed    
    
    
    
24. FADAVI Z, Alizadeh H, Mowla SJ, Soltani BM, et al
    MEF2C induces intrinsic apoptosis and reverses cisplatin resistance in A2780 ovarian cancer cell line.
    BMC Cancer. 2025 Nov 24. doi: 10.1186/s12885-025-15348.
    PubMed     Abstract available
    
    
    
25. LOZA P, Irmejs A, Daneberga Z, Maksimenko J, et al
    The difference in contralateral breast cancer and ovarian cancer risks for BRCA1 founder variant (c.5266dup, c.4035del) carriers with primary breast cancer.
    BMC Cancer. 2025;25:1769.
    PubMed     Abstract available
    
    
    
26. KIM JY, Shin HY, Haque R, Kang ES, et al
    PLCD1 expression for early detection and prognosis in High-Grade serous ovarian cancer.
    BMC Cancer. 2025;25:1741.
    PubMed     Abstract available
    
    
    
27. WANG Y, Chao Q, Lu X, Zhou Y, et al
    Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 cases.
    BMC Cancer. 2025;25:1729.
    PubMed     Abstract available
    
    
    October 2025
28. TRAN NL, Wang Y, Quinn KM, Bilandzic M, et al
    Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction.
    BMC Cancer. 2025;25:1674.
    PubMed     Abstract available
    
    
    
29. JIAO H, Tian J, Liu Q, Jiang M, et al
    Analysis of FNDC1 as a diagnostic marker and potential therapeutic target for ovarian serous cancer.
    BMC Cancer. 2025;25:1595.
    PubMed     Abstract available
    
    
    
30. AMMOUS-BOUKHRIS N, Abdelmaksoud-Dammak R, Ben Kridis W, Ben-Ayed-Guerfali D, et al
    Germline and somatic mutational variants of Tunisian high grade serous ovarian cancer identified by next-generation sequencing.
    BMC Cancer. 2025;25:1542.
    PubMed     Abstract available
    
    
    
31. WU H, Lin R, Hong L
    ACOXL-AS1's pan-cancer dynamics and its proliferative impact on endometrial endometrioid carcinoma.
    BMC Cancer. 2025;25:1522.
    PubMed     Abstract available
    
    
    September 2025
32. NIKEGHBAL P, Zamanian D, Burke D, Steinkamp MP, et al
    Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients.
    BMC Cancer. 2025;25:1459.
    PubMed     Abstract available
    
    
    August 2025
33. JIN Y, Wang W, Wu M, Fan Y, et al
    Clinicopathological features of Chinese ovarian cancer patients with double heterozygosity for cancer-predisposed genes.
    BMC Cancer. 2025;25:1391.
    PubMed     Abstract available
    
    
    
34. TIAN Y, Li J, Dong R, Guan Y, et al
    ADAMTS2 mediates epithelial?mesenchymal transition and inflammation in high-grade serous ovarian cancer: a study based on bioinformatic analyses and experiments.
    BMC Cancer. 2025;25:1376.
    PubMed     Abstract available
    
    
    
35. APELIAN S, Hamdan A, Mohammad R, Abbas A, et al
    Epidemiological and clinicopathological characteristics of ovarian cancer in Syria during the war years: a national multicenter retrospective study (2017-2021).
    BMC Cancer. 2025;25:1359.
    PubMed     Abstract available
    
    
    
36. PARK S, Kim H, Wee CW, Kim YS, et al
    Radiotherapy quality assurance program of ongoing clinical trial using stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a dummy run study of a prospective, randomized, multicenter phase III trial (KGOG 3064/KROG 2204).
    BMC Cancer. 2025;25:1336.
    PubMed     Abstract available
    
    
    
37. YU G, Wei F, Li W, Guo Q, et al
    FAM111B knockdown attenuates tumorigenesis of ovarian cancer via the downregulation of MYC.
    BMC Cancer. 2025;25:1290.
    PubMed     Abstract available
    
    
    July 2025
38. FENG Y, Chen Y, Wu Q, Bao Z, et al
    A retrospective case series at a tertiary hospital in china: ultrasonographic features of Struma ovarii.
    BMC Cancer. 2025;25:1180.
    PubMed     Abstract available
    
    
    
39. DANG C, Wang R, Shi Y, Liu P, et al
    Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer's risk: a drug-target Mendelian randomization study.
    BMC Cancer. 2025;25:1125.
    PubMed     Abstract available
    
    
    
40. LEMAN R, Cherifi F, Leheurteur M, Theret P, et al
    Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).
    BMC Cancer. 2025;25:1075.
    PubMed     Abstract available
    
    
    
41. COSTANZO S, Godino L, De Summa S, Marvulli TM, et al
    BRCA cascade counselling and testing in Italy: current position and future directions.
    BMC Cancer. 2025;25:1044.
    PubMed     Abstract available
    
    
    May 2025
42. LIU H, Luo M, Peng C, Cheng X, et al
    Clinical efficacy analysis of chemotherapy of isolated neck lymphatic metastasis in advanced epithelial ovarian cancer.
    BMC Cancer. 2025;25:969.
    PubMed     Abstract available
    
    
    
43. GUAN X, Liao S, Zhang F, Zhu Q, et al
    Identifying the germline variation spectrum and predisposition genes in Chinese ovarian cancer using whole exome sequencing.
    BMC Cancer. 2025;25:924.
    PubMed     Abstract available
    
    
    
44. LENG Y, Zhou J, Liu W, Luo F, et al
    A CT-based radiomics model for predicting progression-free survival in patients with epithelial ovarian cancer.
    BMC Cancer. 2025;25:899.
    PubMed     Abstract available
    
    
    
45. CHUFFA LGA, Fioruci-Fontanelli BA, Mendes LO, Ferreira Seiva FR, et al
    Retraction Note: Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.
    BMC Cancer. 2025;25:876.
    PubMed    
    
    
    
46. GUO W, Yin J, Gu Y, Shan Y, et al
    Patients with macroscopic lymph node metastasis expect poor prognosis after neoadjuvant chemotherapy in advanced ovarian cancer: a retrospective cohort study based on a single gynecological team.
    BMC Cancer. 2025;25:832.
    PubMed     Abstract available
    
    
    April 2025
47. STOER NC, Botteri E, Lindemann K, Langseth H, et al
    Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway.
    BMC Cancer. 2025;25:807.
    PubMed     Abstract available
    
    
    
48. YAHATA T, Toujima S, Sasaki I, Iwahashi N, et al
    Adeno-associated virus-clustered regularly interspaced short palindromic repeats/cas9?mediated ovarian cancer treatment targeting PD-L1.
    BMC Cancer. 2025;25:749.
    PubMed     Abstract available
    
    
    
49. TIAN L, Gao Y, Zi L, Zhe R, et al
    Dual Cas12a and multiplex crRNA CRISPR strategy ultrasensitive detection novel circRNA biomarker for the diagnosis of ovarian cancer.
    BMC Cancer. 2025;25:695.
    PubMed     Abstract available
    
    
    
50. TARAPARA B, Shah F
    Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer.
    BMC Cancer. 2025;25:650.
    PubMed     Abstract available
    
    
    March 2025
51. KIM NI, Koo JY, Kim SS, Lee JY, et al
    Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy.
    BMC Cancer. 2025;25:540.
    PubMed     Abstract available
    
    
    
52. WU VS, Smith A', Russell H, Bamgboje-Ayodele A, et al
    Assessing the impact of a self-guided digital intervention for fear of cancer recurrence (iConquerFear) in ovarian cancer survivors: a pilot randomised waitlist-controlled trial.
    BMC Cancer. 2025;25:527.
    PubMed     Abstract available
    
    
    
53. OLORUNFEMI G, Libhaber E, Ezechi OC, Musenge E, et al
    Trends in national and ethnic burden of ovarian cancer mortality in South Africa (1999-2018): a population based, age-period-cohort and join point regression analyses.
    BMC Cancer. 2025;25:515.
    PubMed     Abstract available
    
    
    
54. MARBACH D, Brouer-Visser J, Brennan L, Wilson S, et al
    Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).
    BMC Cancer. 2025;25:500.
    PubMed     Abstract available
    
    
    
55. WANG H, Tu T, Yin L, Liu Z, et al
    Single nucleotide polymorphisms in ovarian cancer impacting lipid metabolism and prognosis: an integrated TCGA database analysis.
    BMC Cancer. 2025;25:462.
    PubMed     Abstract available
    
    
    February 2025
56. QIN Y, Chen XY, Cao F, Liu JC, et al
    Pre- and post-diagnosis dietary patterns and overall survival in patients with epithelial ovarian cancer: a prospective cohort study.
    BMC Cancer. 2025;25:363.
    PubMed     Abstract available
    
    
    
57. SHI W, Zhang Y, Cheng S, Zhao Y, et al
    Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis.
    BMC Cancer. 2025;25:355.
    PubMed     Abstract available
    
    
    
58. ZHANG H, Liu M, Zhong H, Ma L, et al
    Mechanistic role of FN1 in LAIR-1 mediated downregulation of ovarian cancer cell proliferation.
    BMC Cancer. 2025;25:339.
    PubMed     Abstract available
    
    
    
59. LI Y, Song W, Gao P, Guan X, et al
    Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021.
    BMC Cancer. 2025;25:330.
    PubMed     Abstract available
    
    
    
60. YANG N, Zhou X, Gong Y, Deng Z, et al
    The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.
    BMC Cancer. 2025;25:294.
    PubMed     Abstract available
    
    
    
61. YE Q, Qi Y, Liu J, Hu Y, et al
    A predictive model for recurrence in patients with borderline ovarian tumor based on neural multi-task logistic regression.
    BMC Cancer. 2025;25:281.
    PubMed     Abstract available
    
    
    
62. GUPTA VG, Roby KF, Pathak HB, Godwin AK, et al
    The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model.
    BMC Cancer. 2025;25:233.
    PubMed     Abstract available
    
    
    January 2025
63. KAUTZ-FREIMUTH S, Shukri A, Stracke C, Isselhard A, et al
    Factors influencing role preferences in decision-making of healthy women with BRCA1/2 pathogenic variants: subanalysis from a randomised controlled decision coaching trial.
    BMC Cancer. 2025;25:164.
    PubMed     Abstract available
    
    
    
64. CHEN W, Yan L, Li Q, Zhou S, et al
    Molecular subtype of ovarian clear cell carcinoma: an analysis of 80 Chinese patients using the TCGA molecular classification of endometrial cancer.
    BMC Cancer. 2025;25:90.
    PubMed     Abstract available
    
    
    December 2024
65. WANG X, Tian W, Wang N, Yang X, et al
    Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study.
    BMC Cancer. 2024;24:1593.
    PubMed     Abstract available
    
    
    
66. ZHANG Y, Guan Y, Xiao X, Xu S, et al
    Circulating tumor DNA detection improves relapse prediction in epithelial ovarian cancer.
    BMC Cancer. 2024;24:1565.
    PubMed     Abstract available
    
    
    
67. HUO C, Wu B, Ye D, Xu M, et al
    New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer.
    BMC Cancer. 2024;24:1536.
    PubMed     Abstract available
    
    
    
68. SCHMIDT M, Vernooij R, van Nuland M, Smeijsters E, et al
    Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival.
    BMC Cancer. 2024;24:1553.
    PubMed     Abstract available
    
    
    
69. ANDRIKOPOULOU A, Zagouri F, Goula K, Haidopoulos D, et al
    Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies.
    BMC Cancer. 2024;24:1503.
    PubMed     Abstract available
    
    
    November 2024
70. IYOSHI S, Kimura M, Yoshihara M, Kunishima A, et al
    Detailed analysis of the histology-specific impact of ascites volume on the outcome of epithelial ovarian cancer: a multi-institutional retrospective cohort study.
    BMC Cancer. 2024;24:1479.
    PubMed     Abstract available
    
    
    
71. MENG Y, Meng Y, Zheng H, Huo J, et al
    METTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via regulation of the mTOR/AKT pathway and its link to the tumor immune microenvironment.
    BMC Cancer. 2024;24:1455.
    PubMed     Abstract available
    
    
    
72. QIAN C, Xing Y, Cheng W
    Causal effect between breast cancer and ovarian cancer: a two-sample mendelian randomization study.
    BMC Cancer. 2024;24:1433.
    PubMed     Abstract available
    
    
    
73. CHAO A, Huang CY, Yu W, Lin CY, et al
    Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.
    BMC Cancer. 2024;24:1403.
    PubMed     Abstract available
    
    
    
74. FU YP, Lin H, Ou YC, Wu CH, et al
    Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer.
    BMC Cancer. 2024;24:1377.
    PubMed     Abstract available
    
    
    
75. MAURER T, Belau MH, Zyriax BC, Welsch G, et al
    Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial.
    BMC Cancer. 2024;24:1379.
    PubMed     Abstract available
    
    
    
76. YANG S, Wang J, Du Z, Sheng C, et al
    An in vitro investigation into the cytotoxic impact of antigen-presenting dendritic cell-tumor infiltrating lymphocytes on ovarian cancer cells.
    BMC Cancer. 2024;24:1364.
    PubMed     Abstract available
    
    
    October 2024
77. MOUSAVI A, Eshraghi N, Akhavan S, Sheikhhasani S, et al
    Clinical features and survival rate of patients with ovarian granulosa cell tumor in Iran; a 10-year retrospective study.
    BMC Cancer. 2024;24:1318.
    PubMed     Abstract available
    
    
    
78. CARUCCI M, Clamp A, Zhou C, Hurt C, et al
    The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.
    BMC Cancer. 2024;24:1309.
    PubMed     Abstract available
    
    
    
79. ZHAO JJ, Zhao J, Lin F, Xu LL, et al
    A quinoline-2-thione derivative as a novel chemotherapy drug candidate displays anti-tumor activity in vitro and in vivo.
    BMC Cancer. 2024;24:1272.
    PubMed     Abstract available
    
    
    September 2024
80. SHUANG T, Wu S, Zhao Y, Yang Y, et al
    The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian cancer cells.
    BMC Cancer. 2024;24:1213.
    PubMed     Abstract available
    
    
    August 2024
81. LIAO W, Li J, Feng W, Kong W, et al
    Pan-immune-inflammation value: a new prognostic index in epithelial ovarian cancer.
    BMC Cancer. 2024;24:1052.
    PubMed     Abstract available
    
    
    
82. LIU D, Li R, Wang Y, Li D, et al
    Identification and validation of genes associated with prognosis of cisplatin-resistant ovarian cancer.
    BMC Cancer. 2024;24:508.
    PubMed     Abstract available
    
    
    July 2024
83. JI J, Bi F, Zhang X, Zhang Z, et al
    Single-cell transcriptome analysis revealed heterogeneity in glycolysis and identified IGF2 as a therapeutic target for ovarian cancer subtypes.
    BMC Cancer. 2024;24:926.
    PubMed     Abstract available
    
    
    
84. RUBIO MJ, Manzano A, de Sande LM, Estevez-Garcia P, et al
    Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.
    BMC Cancer. 2024;24:803.
    PubMed     Abstract available
    
    
    June 2024
85. DE MORAES FCA, Sudo RYU, Souza MEC, Fernandes MR, et al
    The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients.
    BMC Cancer. 2024;24:712.
    PubMed     Abstract available
    
    
    
86. BENTESTUEN M, Ladekarl M, Knudsen A, Zacho HD, et al
    Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial.
    BMC Cancer. 2024;24:699.
    PubMed     Abstract available
    
    
    
87. THOREL L, Divoux J, Lequesne J, Babin G, et al
    The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
    BMC Cancer. 2024;24:701.
    PubMed     Abstract available
    
    
    May 2024
88. LI J, Yang Z, Wang T, Li M, et al
    Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
    BMC Cancer. 2024;24:667.
    PubMed     Abstract available
    
    
    
89. SOLHEIM ET, Gerking Y, Krakenes T, Herdlevaer I, et al
    Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell proliferation following knockout of CDR2L.
    BMC Cancer. 2024;24:645.
    PubMed     Abstract available
    
    
    
90. WANG T, Wang X, Wu J, Li X, et al
    Causal relationship between thyroid dysfunction and ovarian cancer: a two-sample Mendelian randomization study.
    BMC Cancer. 2024;24:629.
    PubMed     Abstract available
    
    
    
91. LI C, Cui Q, Wang X, Yao S, et al
    CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
    BMC Cancer. 2024;24:609.
    PubMed     Abstract available
    
    
    
92. QUAN C, Chen X, Wen H, Wu X, et al
    Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    BMC Cancer. 2024;24:565.
    PubMed     Abstract available
    
    
    
93. XIE W, Zhang L, Shen J, Lai F, et al
    Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis.
    BMC Cancer. 2024;24:551.
    PubMed     Abstract available
    
    
    April 2024
94. CAI X, Lin J, Liu L, Zheng J, et al
    A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
    BMC Cancer. 2024;24:515.
    PubMed     Abstract available
    
    
    
95. DE OLIVEIRA FERREIRA C, Carneiro VCG, Araujo Mariz C
    Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
    BMC Cancer. 2024;24:499.
    PubMed     Abstract available
    
    
    March 2024
96. FANG CH, Cheng WF, Cheng YF, Lan KL, et al
    Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes.
    BMC Cancer. 2024;24:395.
    PubMed     Abstract available
    
    
    
97. ALWAFAI Z, Beck MH, Fazeli S, Gurtler K, et al
    Accuracy of endometrial sampling in the diagnosis of endometrial cancer: a multicenter retrospective analysis of the JAGO-NOGGO.
    BMC Cancer. 2024;24:380.
    PubMed     Abstract available
    
    
    
98. YANG S, Du J, Wang W, Zhou D, et al
    APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer.
    BMC Cancer. 2024;24:364.
    PubMed     Abstract available
    
    
    
99. HE D, Zhang X, Chang Z, Liu Z, et al
    Survival time prediction in patients with high-grade serous ovarian cancer based on (18)F-FDG PET/CT- derived inter-tumor heterogeneity metrics.
    BMC Cancer. 2024;24:337.
    PubMed     Abstract available
    
    
    
100. NIE X, Gao L, Zheng M, Wang S, et al
     ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer.
     BMC Cancer. 2024;24:330.
     PubMed     Abstract available
     
     
     
101. LENG Y, Kan A, Wang X, Li X, et al
     Contrast-enhanced CT radiomics for preoperative prediction of stage in epithelial ovarian cancer: a multicenter study.
     BMC Cancer. 2024;24:307.
     PubMed     Abstract available
     
     
     
102. YAACOUB S, Hajj L, Khairallah A
     A clinicopathological study about the epidemiology of granulosa cell tumors in Lebanon.
     BMC Cancer. 2024;24:309.
     PubMed     Abstract available
     
     
     February 2024
103. WU M, Gu S, Yang J, Zhao Y, et al
     Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer.
     BMC Cancer. 2024;24:267.
     PubMed     Abstract available
     
     
     
104. YOU Y, Yang Q
     Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single?cell RNA sequencing data.
     BMC Cancer. 2024;24:207.
     PubMed     Abstract available
     
     
     
105. JAMALZADEH S, Dai J, Lavikka K, Li Y, et al
     Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.
     BMC Cancer. 2024;24:173.
     PubMed     Abstract available
     
     
     January 2024
106. SONG G, Sun Z, Chu M, Zhang Z, et al
     FBXO28 promotes cell proliferation, migration and invasion via upregulation of the TGF-beta1/SMAD2/3 signaling pathway in ovarian cancer.
     BMC Cancer. 2024;24:122.
     PubMed     Abstract available
     
     
     
107. YU JH, Tong CJ, Huang QD, Ye YL, et al
     Long-term outcomes of pelvic exenterations for gynecological malignancies: a single-center retrospective cohort study.
     BMC Cancer. 2024;24:88.
     PubMed     Abstract available
     
     
     
108. WEIGELT J, Petrosyan M, Oliveira-Ferrer L, Schmalfeldt B, et al
     Ovarian cancer cells regulate their mitochondrial content and high mitochondrial content is associated with a poor prognosis.
     BMC Cancer. 2024;24:43.
     PubMed     Abstract available
     
     
     December 2023
109. WANG H, Chen C, Wang D, Zhu Y, et al
     Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.
     BMC Cancer. 2023;23:1210.
     PubMed     Abstract available
     
     
     November 2023
110. LIU S, Yan Y, Cui Z, Feng H, et al
     Relationship between PIWIL1 gene polymorphisms and epithelial ovarian cancer susceptibility among southern Chinese woman: a three-center case-control study.
     BMC Cancer. 2023;23:1149.
     PubMed     Abstract available
     
     
     
111. YANG Y, Ye X, Zhou B, Liu Y, et al
     Nomogram for predicting lymph node metastasis in patients with ovarian cancer using ultrasonography: a multicenter retrospective study.
     BMC Cancer. 2023;23:1121.
     PubMed     Abstract available
     
     
     
112. VOGEL RI, Stenzel AE, Lee H, Hunter-Schlichting D, et al
     Prevalence of active cytomegalovirus infection at diagnosis of ovarian cancer and during chemotherapy and subsequent changes in cognitive functioning.
     BMC Cancer. 2023;23:1057.
     PubMed     Abstract available
     
     
     October 2023
113. KIM YB, Byun HK, Wee CW, Kim H, et al
     Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC).
     BMC Cancer. 2023;23:1014.
     PubMed     Abstract available
     
     
     
114. ELSHAMI M, Al-Madhoun S, Alser M, Al-Slaibi I, et al
     Anticipated time to seek medical advice for possible ovarian cancer symptoms and perceived barriers to early presentation among Palestinian women: a national cross-sectional study.
     BMC Cancer. 2023;23:975.
     PubMed     Abstract available
     
     
     
115. DOBILAS A, Jansaker F, Li X, Sundquist K, et al
     Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden.
     BMC Cancer. 2023;23:951.
     PubMed     Abstract available
     
     
     September 2023
116. CHEN L, Tang Q, Zhang K, Huang Q, et al
     Altered expression of the L-arginine/nitric oxide pathway in ovarian cancer: metabolic biomarkers and biological implications.
     BMC Cancer. 2023;23:844.
     PubMed     Abstract available
     
     
     August 2023
117. O'BRIEN S, Butticello M, Thompson C, Wilson B, et al
     Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.
     BMC Cancer. 2023;23:775.
     PubMed     Abstract available
     
     
     
118. OFVERHOLM A, Torngren T, Rosen A, Arver B, et al
     Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
     BMC Cancer. 2023;23:738.
     PubMed     Abstract available
     
     
     July 2023
119. CHITRANGI S, Vaity P, Jamdar A, Bhatt S, et al
     Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
     BMC Cancer. 2023;23:689.
     PubMed     Abstract available
     
     
     
120. BATISTA MP, Roffe M, Romero I, Lopez-Guerrero JA, et al
     Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progression.
     BMC Cancer. 2023;23:613.
     PubMed     Abstract available
     
     
     
121. GEBHART P, Singer CF, Gschwantler-Kaulich D
     CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study.
     BMC Cancer. 2023;23:610.
     PubMed     Abstract available
     
     
     
122. CHEN S, Lu H, Jiang S, Li M, et al
     An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China.
     BMC Cancer. 2023;23:608.
     PubMed     Abstract available
     
     
     June 2023
123. HALLSSON LR, Sroczynski G, Engel J, Siebert U, et al
     Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.
     BMC Cancer. 2023;23:590.
     PubMed     Abstract available
     
     
     
124. LI X, Li X, Hu Y, Liu O, et al
     PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation.
     BMC Cancer. 2023;23:573.
     PubMed     Abstract available
     
     
     
125. MALEKI Z, Vali M, Nikbakht HA, Hassanipour S, et al
     Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis.
     BMC Cancer. 2023;23:558.
     PubMed     Abstract available
     
     
     May 2023
126. DUAN C, Li K, Pan X, Wei Z, et al
     Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.
     BMC Cancer. 2023;23:489.
     PubMed     Abstract available
     
     
     
127. FANALE D, Brando C, Corsini LR, Cutaia S, et al
     Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
     BMC Cancer. 2023;23:437.
     PubMed     Abstract available
     
     
     April 2023
128. MELKI R, Melloul M, Aissaoui S, El Harroudi T, et al
     Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
     BMC Cancer. 2023;23:339.
     PubMed     Abstract available
     
     
     
129. LI J, Liang H, Xiao W, Wei P, et al
     Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2.
     BMC Cancer. 2023;23:321.
     PubMed     Abstract available
     
     
     
130. REIJONEN M, Holopainen E, Arponen O, Kononen M, et al
     Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer.
     BMC Cancer. 2023;23:299.
     PubMed     Abstract available
     
     
     March 2023
131. LIU S, Feng S, Du F, Zhang K, et al
     Association of smoking, alcohol, and coffee consumption with the risk of ovarian cancer and prognosis: a mendelian randomization study.
     BMC Cancer. 2023;23:256.
     PubMed     Abstract available
     
     
     
132. BATES KM, Vathiotis I, MacNeil T, Ahmed FS, et al
     Spatial characterization and quantification of CD40 expression across cancer types.
     BMC Cancer. 2023;23:220.
     PubMed     Abstract available
     
     
     June 2021
133. REID BM, Vyas S, Chen Z, Chen A, et al
     Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
     BMC Cancer. 2021;21:714.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum